Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ImmunoCellular Therapeutics Ltd (NYSE MKT LLC:IMUC)

During the Trading Day
0.471 -0.004 / -0.84%
As of 3:57pm ET
Day’s Change
During After-Hours   Switch to standard view »
0.48 +0.009 / +1.91%
Volume: 12.3K
Health Technology

Company Description

ImmunoCellular Therapeutics Ltd. is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers. Immunotherapy is an emerging approach to treating cancer in which a patients own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. Its cell-based vaccine technologies are primary platform technologies and commercial prospects will be heavily dependent on the outcome of the contemplated clinical trials for current lead vaccine product candidate. Its product pipeline includes peptide based vaccine to target cancer stem cells, cellular immunotherapies to target cancer associated antigens, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular product candidates include ICT-107, CT-121, ICT-109, ICT-037, ICT-69 and CT-Diagnostic-SCLC. Its antibodies are designed to treat small cell lung cancer, pancreatic cancer, multiple myeloma and ovarian cancer. The company was founded by John S. Yu on March 20, 1987 and is headquartered in Woodland Hills, CA.

Contact Information

ImmunoCellular Therapeutics Ltd.
23622 Calabasas Road
Calabasas California 91302
P:(818) 264-2300
Investor Relations:



Mutual fund holders3.77%
Other institutional13.77%
Individual stakeholders1.57%

Top Executives

John S. YuChairman, Secretary & Chief Scientific Officer
Andrew GengosPresident, Chief Executive Officer & Director
Steven J. SwansonSenior Vice President-Research
Anthony J. GringeriSenior Vice President-Strategic Resources
David E. FractorChief Accounting Officer & Vice President-Finance